Compare NNOX & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNOX | EQ |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.0M | 129.0M |
| IPO Year | 2019 | 2018 |
| Metric | NNOX | EQ |
|---|---|---|
| Price | $1.12 | $2.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 3.9M | 1.0M |
| Earning Date | 04-20-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | $147.55 | N/A |
| Revenue Next Year | $81.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.36 |
| 52 Week High | $5.69 | $3.54 |
| Indicator | NNOX | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 42.99 |
| Support Level | $0.73 | $1.76 |
| Resistance Level | $1.44 | $2.61 |
| Average True Range (ATR) | 0.12 | 0.29 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 23.81 | 19.07 |
Nano X Imaging Ltd is focused on driving the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. The group combines affordable imaging hardware, progressive AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. The three segments are composed of the Nanox.ARC segment, the AI and software solutions segment, and the Radiology services segment. Key revenue is generated from Radiology Services.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.